<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03911076</url>
  </required_header>
  <id_info>
    <org_study_id>PVX2TACIN17368</org_study_id>
    <nct_id>NCT03911076</nct_id>
  </id_info>
  <brief_title>Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL</brief_title>
  <acronym>PVX-2</acronym>
  <official_title>A Randomized Double-Blind, Placebo-controlled Phase II Trial With Safety Run-In of Intramuscular pNGVL4a-Sig/E7(Detox)/HSP70 and TA-CIN for the Treatment of Patients With HPV16+ Atypical Squamous Cells of Undetermined Significance (ASC-US) or Cannot Exclude High Grade SIL (ASC-H) Cytology or Low-grade Squamous Intraepithelial Lesion (LSIL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PapiVax Biotech, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PapiVax Biotech, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate the safety and tolerability of the dual IM pNGVL4a Sig/E7(detox)/HSP70 DNA&#xD;
           and single IM TA-CIN immunization regimen&#xD;
&#xD;
        -  To evaluate the efficacy of dual IM pNGVL4a-Sig/E7(detox)/HSP70 DNA and single IM TA-CIN&#xD;
           immunization regimen on Human Papillomavirus (HPV) 16 clearance by Month 6&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2019</start_date>
  <completion_date type="Anticipated">January 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Safety run-in followed by randomized double-blind, placebo-controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Safety run-in is open label (no control), followed by randomized double-blind, placebo-controlled study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the safety and tolerability of the dual IM pNGVL4a Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of patients that have cleared HPV16 at Month 6</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the efficacy of dual IM pNGVL4a-Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen on Human Papillomavirus (HPV) 16 clearance by Month 6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of patients that have cleared HPV16 at Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the efficacy of dual IM pNGVL4a-Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen on maintenance of Human Papillomavirus (HPV) 16 clearance by Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of patients that have normal cytology at Month 6</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the efficacy of dual IM pNGVL4a-Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen on regression to cytology with no evidence of intraepithelial lesion or malignancy (NILM) at Month 6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>ASC-US</condition>
  <condition>ASC-H Atypical Squamous Cells, Cannot Rule Out High-Grade Squamous Intra-Epithelial Lesion</condition>
  <condition>LSIL</condition>
  <arm_group>
    <arm_group_label>PVX-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prime: 3 mg pNGVL4a-Sig/E7(detox)/HSP70 DNA Boost: 0.1 mg TA-CIN protein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Prime: PBS (Phosphate Buffered Saline) Boost: PGC (Phosphate Glycine Cysteine Buffer)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PVX-2</intervention_name>
    <description>pNGVL4a-Sig/E7(detox)/HSP70 (naked DNA plasmid priming vaccine) TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)</description>
    <arm_group_label>PVX-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PBS and PGC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female subjects age 25-70 years with confirmation of ASC-US, ASC-H, or LSIL by&#xD;
             liquid-based cytology&#xD;
&#xD;
          2. HIV uninfected&#xD;
&#xD;
          3. Patients whose cytologic specimen is HPV16+ by Aptima HPV 16 18/45 Genotype Assay&#xD;
&#xD;
          4. Body Mass Index â‰¤ 32 kg/m2&#xD;
&#xD;
          5. Hepatitis B surface antigen negative&#xD;
&#xD;
          6. Anti-hepatitis C virus antibody (anti-HCV) negative or negative HCV PCR if anti-HCV&#xD;
             positive&#xD;
&#xD;
          7. Patients who are able and willing to comply with all study procedures and voluntarily&#xD;
             sign an informed consent form, and with anticipated availability for the planned&#xD;
             follow-up period of one year&#xD;
&#xD;
          8. Patients who are of childbearing potential agree to remain sexually abstinent, use&#xD;
             methods of contraception (e.g. oral contraception, barrier methods, spermicide,&#xD;
             intrauterine device (IUD)), or have a partner who is sterile (i.e., vasectomy) through&#xD;
             6 months.&#xD;
&#xD;
          9. Patients must have adequate organ function at the time of enrollment as defined by the&#xD;
             following parameters: white blood cell count &gt;3,000/mcL; lymphocyte number &gt;500/mcL;&#xD;
             absolute neutrophil count &gt;1,000/mcL; platelets &gt;90,000/mcL; hemoglobin &gt;9 g/dL; total&#xD;
             bilirubin &lt;3 X the institutional limit of normal; aspartate aminotransferase (AST&#xD;
             [SGOT]) / alanine aminotransferase (ALT [SGPT]) &lt;3 X the institutional limit of&#xD;
             normal; creatinine &lt;2.5X the institutional limit of normal.&#xD;
&#xD;
         10. Histologic diagnosis of &lt;CIN2 upon screening colposcopic examination with mandatory&#xD;
             ECC, and cervical biopsy(ies) as clinically indicated.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are attempting pregnancy within 6 months, pregnant, or breastfeeding.&#xD;
&#xD;
          2. Patients with immunodeficiency, or treatment with immunosuppressive medications&#xD;
&#xD;
          3. Administration of any blood product within 3 months of enrollment.&#xD;
&#xD;
          4. Administration of any licensed vaccine within 2 weeks of enrollment (4weeks for&#xD;
             measles vaccine)&#xD;
&#xD;
          5. Participation in a study with an investigational compound or device within 30 days of&#xD;
             signing informed consent.&#xD;
&#xD;
          6. History of seizures (unless seizure free for 5 years)&#xD;
&#xD;
          7. Patients with positive serological test for human immunodeficiency virus (HIV).&#xD;
&#xD;
          8. Previous cancer history within the past 5 years.&#xD;
&#xD;
          9. Patients who have had chemotherapy, radiation, biological cancer therapy, or other&#xD;
             investigational agents within 28 days prior to the first dose of study drug.&#xD;
&#xD;
         10. Patients who have had surgery within 28 days, excluding minor procedures (dental work,&#xD;
             skin biopsy, etc).&#xD;
&#xD;
         11. Patients with an uncontrolled intercurrent illness including, but not limited to,&#xD;
             ongoing, or active infection, symptomatic congestive heart failure, unstable angina&#xD;
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements.&#xD;
&#xD;
         12. Patients who have an active autoimmune disease (e.g., rheumatoid arthritis, systemic&#xD;
             lupus erythematosus (SLE), ulcerative colitis, Crohn's Disease, multiple sclerosis&#xD;
             (MS), ankylosing spondylitis).&#xD;
&#xD;
         13. Patients with a recognized immunodeficiency disease including cellular&#xD;
             immunodeficiencies, hypogammaglobulinemia, or dysgammaglobulinemia; patients who have&#xD;
             acquired, hereditary, or congenital immunodeficiencies; patients being chronically&#xD;
             treated with immunosuppressive drugs such as cyclosporin, adrenocorticotropic hormone&#xD;
             (ACTH), or systemic corticosteroids&#xD;
&#xD;
         14. Previous cervical conization or LEEP procedure or previous total hysterectomy due to&#xD;
             cervical lesions at enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patients with cervical cytologic diagnosis of ASC-US, ASC-H, or LSIL</gender_description>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wendy Wu, MS</last_name>
    <phone>+886282268451</phone>
    <email>wendy@papivax.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lissette Molina, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health Awareness, Inc.</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Blomer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Corpus Christi Women's Clinic (Elligo Health Research, Inc.)</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78412</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charles Kirkham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atypical Squamous Cells of the Cervix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

